<DOC>
	<DOC>NCT02371174</DOC>
	<brief_summary>The primary objective of the study is to clarify factors affecting the incidence of peripheral neuropathy in patients treated with HALAVEN. A total of 590 patients will be enrolled in this study with 295 patients in the treatment group of primary or secondary chemotherapy and 295 patients in the treatment group of tertiary or later chemotherapy.</brief_summary>
	<brief_title>Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>Inclusion criteria: Patients with HER2negative inoperable or recurrent breast cancer. Exclusion criteria: Patients with highgrade bone marrow depression (absolute neutrophil count less than 1,000 /mm^3, absolute platelet count less than 75,000 /mm^3). Patients with a history of hypersensitivity to the ingredients of HALAVEN. Women who are pregnant or may be pregnant. Patients with a history of use of HALAVEN.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HER2-Negative Inoperable or Recurrent Breast Cancer</keyword>
	<keyword>Japan</keyword>
	<keyword>Eribulin Mesylate</keyword>
</DOC>